D&A at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s D&A?
- Candel Therapeutics, Inc. (CADL) reported D&A of $149K in Q1 2026.
- How has Candel Therapeutics, Inc.'s D&A changed year-over-year?
- Candel Therapeutics, Inc.'s D&A decreased by 39.2% year-over-year, from $245K to $149K.
- What is the long-term trend for Candel Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s D&A has grown at a 36.6% compound annual growth rate (CAGR), from $232K to $808K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.